Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris Parker, Dominic Hague, Raj Persad et al.|The Lancet|2024Cited by 50
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E. Langley, Mahesh Parmar, Duncan C. Gilbert et al.|The Lancet|2021Cited by 49
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Carmel Pezaro, Laura Murphy et al.|The Lancet Oncology|2026Cited by 3